Arava

Drug Overview

Living with the daily burden of chronic pain, joint destruction, and systemic autoimmune conditions like Rheumatoid Arthritis can feel overwhelming. When the immune system mistakenly attacks the body’s own tissues, finding a treatment that can halt this process is critical to preserving long-term mobility. In Rheumatology, conventional therapies are utilized as the first line of defense to stop joint deterioration. Arava is a foundational medication designed to calm the immune system, reduce painful symptoms, and protect your joints from permanent mechanical damage.

Arava is a conventional synthetic DMARD (Disease-Modifying Antirheumatic Drug). Unlike a highly engineered, injectable Biologic, Arava is an oral medication that works systemically to slow down the hyperactive immune response.

• Generic Name: Leflunomide
• US Brand Names: Arava
• Drug Class: Non-biologic DMARD (Pyrimidine Synthesis Inhibitor)
• Route of Administration: Oral tablet
• FDA Approval Status: Fully FDA-approved for the treatment of active Rheumatoid Arthritis in adults.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Arava effectively brings severe joint inflammation under control, we must look at how immune cells multiply. In patients with Rheumatoid Arthritis, specific white blood cells (called T-cells and B-cells) become hyperactive. To cause widespread joint damage, these cells must rapidly divide and multiply, a process that requires a massive amount of cellular energy and genetic building blocks (DNA and RNA).

Arava is a Small Molecule DMARD that directly interrupts this cellular replication. Once swallowed, Arava is quickly converted in the body into its active form, called teriflunomide. This active molecule specifically targets and blocks an enzyme called dihydroorotate dehydrogenase (DHODH).

The DHODH enzyme is absolutely essential for the de novo synthesis of pyrimidines—one of the core structural building blocks required to make new DNA. By inhibiting this enzyme, Arava effectively starves the overactive T-cells and B-cells of the materials they need to reproduce. Because these destructive immune cells can no longer multiply, the body’s production of inflammatory cytokines (such as Tumor Necrosis Factor-alpha and Interleukin-6) plummets. Within the joints, this metabolic blockade permanently stops the formation of the synovial pannus—the thick, inflamed, and invasive tissue that progressively degrades cartilage and bone.

FDA-Approved Clinical Indications

Primary Indication: Treatment of adults with active Rheumatoid Arthritis (RA) to reduce signs and symptoms, inhibit structural damage, and improve physical function.

Other Approved & Off-Label Uses:

• Psoriatic Arthritis (PsA) (Off-label, but commonly used)
• Juvenile Idiopathic Arthritis (JIA) (Off-label)
• Prevention of organ rejection in transplant patients (Off-label)
• Cytomegalovirus (CMV) disease management in solid organ transplants (Off-label)

Primary Rheumatology Indications:

• Rheumatoid Arthritis Symptom Reduction: Prescribed to drastically relieve severe joint swelling, tenderness, and morning stiffness, allowing patients to regain their independence.
• Structural Preservation: Actively slows the radiographic progression of the disease, preventing irreversible mechanical joint deformities, such as bone erosions and joint space narrowing.
• Alternative Anchor Therapy: Serves as a vital foundation therapy for patients who cannot tolerate methotrexate, or it can be used in combination with methotrexate for a stronger therapeutic effect.

Dosage and Administration Protocols

Arava is taken orally as a daily tablet. Because the medication stays in the body for a very long time, doctors previously used a “loading dose” to get the drug levels high quickly, though modern practice often skips this to reduce stomach side effects.

Dose Adjustments and Transitioning:

• Hepatic Impairment: Arava is strictly contraindicated in patients with severe, pre-existing liver disease or severely elevated liver enzymes.
• Renal Impairment: Use with caution; no specific dose adjustments are formally mandated for mild renal impairment, but careful monitoring is required.
• Drug Elimination: If a patient experiences severe toxicity or wishes to become pregnant, the drug can take up to 2 years to leave the body naturally. Doctors use a specialized “washout” procedure using an oral powder called cholestyramine, taken for 11 days, to rapidly pull the drug out of the patient’s system.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Current clinical study data (2020-2026) strongly validates Arava as a highly reliable, frontline DMARD. In major rheumatology trials, patients taking Arava consistently demonstrate rapid, sustained drops in DAS28-ESR scores, reflecting a deep systemic decrease in overall disease activity comparable to methotrexate.

Research confirms that a significant percentage of patients achieve ACR20, ACR50, and ACR70 response rates, signifying major 20% to 70% improvements in joint tenderness and swelling. Furthermore, radiographic progression studies utilizing the modified Sharp score verify that this therapy successfully prevents ongoing structural joint damage. Over years of consistent use, X-rays of patients on Arava show significantly fewer new bone erosions and preserved joint spaces compared to those relying solely on simple painkillers, proving its ability to protect the physical framework of the body.

Safety Profile and Side Effects

Black Box Warning: Arava carries a strict FDA Black Box Warning for two critical reasons. First, it causes severe Embryo-Fetal Toxicity. It must absolutely not be used by pregnant women or women of childbearing potential who are not using reliable contraception, as it causes severe birth defects. Second, it carries a warning for Hepatotoxicity (severe liver injury). It can cause fatal liver failure, especially when combined with other liver-taxing drugs.

Common Side Effects (>10%):

• Diarrhea (very common, especially during the first month)
• Alopecia (temporary thinning of the hair)
• Nausea and stomach pain
• Mild skin rashes
• Elevated blood pressure

Serious Adverse Events:

• Severe Liver Injury: Dangerous elevations in liver enzymes leading to hepatitis or liver failure.
• Interstitial Lung Disease (ILD): Rare but serious inflammation and scarring of the lung tissue, presenting as a sudden, dry cough and shortness of breath.
• Peripheral Neuropathy: Nerve damage in the hands and feet, causing numbness or tingling.
• Cytopenias: Dangerous drops in white blood cell or platelet counts, increasing infection risks.

Management Strategies: Routine laboratory testing is an absolute clinical mandate. Doctors must strictly monitor liver enzymes (ALT and AST) monthly for the first six months. If severe side effects occur, the rapid cholestyramine “washout” procedure is immediately initiated to clear the drug from the bloodstream.

Research Areas

Direct Clinical Connections:

In contemporary Rheumatology research (2020-2026), scientists are actively investigating how pyrimidine synthesis inhibitors like Arava indirectly influence the RANKL pathway. By suppressing the proliferation of inflammatory B-cells, researchers are studying how the drug fundamentally stops osteoclasts (the specialized cells that dissolve bone) from maturing, linking its mechanism directly to long-term cartilage and bone preservation.

Generalization and Modernization:

A massive area of current clinical research involves optimizing combination therapies. Trials actively evaluate the safety and enhanced efficacy of combining a traditional Small Molecule like Arava with modern Targeted Therapy (such as JAK inhibitors) or injectable Biologic agents. The goal is to achieve deep, sustained clinical remission for patients with highly aggressive Rheumatoid Arthritis who do not respond to a single medication.

Severe Disease & Systemic Involvement:

Because Rheumatoid Arthritis can affect the lungs, research continuously evaluates the delicate balance of using Arava. While the drug effectively lowers systemic inflammation, clinical registries actively monitor its rare potential to trigger Interstitial Lung Disease, seeking to identify genetic markers that could predict which patients are at the highest risk for lung complications before they even start the medication.

Disclaimer: The information regarding the association between leflunomide use, the RANKL pathway, and the risks of Interstitial Lung Disease (ILD) reflects clinical research as of early 2026. Because of the Black Box Warning for embryo-fetal toxicity and hepatotoxicity, strict adherence to pregnancy prevention and liver function monitoring is the absolute standard of care. Always follow the individualized monitoring schedule provided by your rheumatologist. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Comprehensive joint X-rays or ultrasounds, baseline pain scores, and the Health Assessment Questionnaire (HAQ-DI) to properly measure starting physical function.
• Organ Function: A Complete Blood Count (CBC) and extensive Liver Function Tests (LFTs) to ensure the internal organs can safely process the treatment.
• Specialized Testing: A negative pregnancy test is an absolute clinical requirement for females of reproductive age before the first dose is given. Strict screening for latent Tuberculosis and Hepatitis B/C is also heavily recommended.
• Screening: Baseline blood pressure monitoring, as Arava can cause hypertension.

Monitoring and Precautions

• Vigilance: Rheumatologists track laboratory markers of inflammation (CRP and ESR) periodically. Liver enzymes (ALT/AST) and blood counts must be monitored monthly for the first six months, and then every 6 to 8 weeks thereafter.
• Lifestyle: Patients are highly encouraged to engage in low-impact exercise and utilize daily joint protection techniques. Total avoidance of alcohol is absolutely critical, as combining alcohol with Arava drastically increases the risk of fatal liver failure.
• “Do’s and Don’ts” for Patients:
  • DO use highly effective, reliable birth control at all times while taking this medication.
  • DO check your blood pressure regularly at home and report any significant increases.
  • DO contact your doctor immediately if you develop sudden shortness of breath, a dry cough, or yellowing of your skin and eyes (jaundice).
  • DON’T consume any alcohol while taking this medication to protect your liver.
  • DON’T try to get pregnant immediately after stopping the pill. You must undergo the 11-day cholestyramine washout procedure and have blood tests confirm the drug is gone first.

Legal Disclaimer

The medical information provided in this guide is for educational and informational purposes only and does not constitute medical advice. While every effort has been made to ensure accuracy based on current rheumatological standards and FDA approvals, medication protocols change rapidly. Always consult a board-certified rheumatologist or qualified healthcare professional before starting, stopping, or altering any medication regimen. Only your physician can determine the appropriate use, dosage, and safety of Arava (leflunomide) for your specific medical condition.